WHO ICTRP trial
IL-6/STAT3 for prediction of response after neoadjuvant chemoradiation therapy…
ChiCTR-OOC-16007907 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR-OOC-16007907 |
|---|---|
| Public title | IL-6/STAT3 for prediction of response after neoadjuvant chemoradiation therapy for stages II-III rectal cancer: a multicenter prospective study. |
| Scientific title | IL-6/STAT for prediction of response after neoadjuvant chemoradiation therapy for stages II-III rectal cancer: a multicenter prospective study. |
| Primary sponsor | Enshi Tujia and Miao Autonomous Prefecture Central Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Observational study |
| Phase | Other |
| Countries | China |
| Conditions | rectal cancer |
| Interventions | Experimental group:Intervention: Eligible patients received pelvic radiotherapy with a dose of 46 Gy, tumor boost of 50Gy over a period of 5 weeks. Patients were given choices between capecitabine 1500 mg/m2 twice daily d1-14 or intravenous… |
| Registration date | Feb 6, 2016 |
| Target size | Experimental group:100 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: